We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Liquid Biopsy Biomarkers for Aggressive Prostate Cancer Discovered

By LabMedica International staff writers
Posted on 05 Jul 2016
Using targeted proteomics on noninvasive liquid biopsies, researchers have discovered biomarkers that provide signatures of aggressive (extracapsular) prostate cancer (PC), which could enable diagnosis before treatment and so help many low-risk PC patients avoid surgery.

Currently, needle biopsies are used to help diagnose PC, but this technique may not detect hidden tumors or cancer that has already spread beyond the organ. More...
The new research advances the quest to develop a precise, noninvasive diagnostic tool that can address over-treatment of slow-growing, low-risk PC.

"We believe we have found a better way that allows us to predict which patients have a slow-growing versus aggressive PC using non-invasive biomarkers. This could eventually help us personalize cancer treatment for these patients," said principal investigator Prof. Dr. Thomas Kislinger, of Princess Margaret Cancer Centre, University Health Network (UHN; Toronto, Canada), and of University of Toronto.

"A fluid-based biomarker would be ideal … to spare patients with indolent (slow-growing) disease from unnecessary procedures, while identifying and treating those who would benefit from treatment intensification," said co-lead author Dr. Yunee Kim.

The Kislinger team – in collaboration with Paul Boutros, Ontario Institute for Cancer Research (Canada), and O. John Semmes, Eastern Virginia Medical School (Norfolk, VA, USA) – used urine samples containing prostatic secretions from 210 patients after they had undergone digital rectal examinations (DRE, the standard clinical "first step" to determine need for further diagnostic testing of the prostate). The research took four years and involved samples from almost 300 patients.

"We used targeted proteomics to accurately quantify hundreds of proteins in urine samples (post-DRE) to identify liquid biopsy signatures. The first round of research involved 80 patients and quantified 150 proteins that were then narrowed down to 34 for further investigation. The next round involved a second, independent cohort of 210 patients,” said Dr. Kislinger, "Applying computational biology, we used the quantitative data from mass spectrometry to develop the fluid biomarkers for aggressive PC." He added, "The next step will be further studies with urine samples from 1,000 international patients to validate if the biomarkers identified have broader clinical utilities in PC."

The study, by Kim Y, Jeon J, et al, was published online ahead of print June 28, 2016, in the journal Nature Communications.

Related Links:
University Health Network



Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
Online QC Software
Acusera 24•7
Multi-Chamber Washer-Disinfector
WD 390
HPV Molecular Test
BD Onclarity HPV Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.